aptaTargets

aptaTargets focuses on therapeutic aptamers and is currently developing ApTOLL, an immunomodulator that represents a new approach to treating the acute phase of ischemic stroke by significantly reducing brain damage. After the successful development in the non-clinical stage and the first-in-human trial (Phase I), the company is providing clinical proof of concept to patients.